MedTrace Logo

Mechanistic Study of Ocrevus

NCT04459988 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2024-05-31

No results posted yet for this study

Summary

The purpose of this study is to investigate the immune cell and other factor changes with Ocrevus in Multiple Sclerosis (MS) patients. Researchers will recruit 35 participants for this study. Patients will be enrolled from the Multiple Sclerosis Center at the University of Michigan Health System in Ann Arbor. The goal of the study is to understand the role of regulatory B cell, T cell and other factors in mediating the therapeutic effects of Ocrevus.

Conditions

Interventions

DRUG

Ocrelizumab

Description Needed

Sponsors & Collaborators

Principal Investigators

  • Yang Mao-Draayer, MD/PHD · University of Michigan

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2022-10-25
Completion
2022-10-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04459988 on ClinicalTrials.gov